DK2683245T3 - Fremgangsmåder og sammensætninger til behandling af depression ved anvendelse af cyclobenzaprin - Google Patents
Fremgangsmåder og sammensætninger til behandling af depression ved anvendelse af cyclobenzaprin Download PDFInfo
- Publication number
- DK2683245T3 DK2683245T3 DK12755254.5T DK12755254T DK2683245T3 DK 2683245 T3 DK2683245 T3 DK 2683245T3 DK 12755254 T DK12755254 T DK 12755254T DK 2683245 T3 DK2683245 T3 DK 2683245T3
- Authority
- DK
- Denmark
- Prior art keywords
- cyclobenzaprine
- compositions
- methods
- treating depression
- depression
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161449838P | 2011-03-07 | 2011-03-07 | |
| PCT/US2012/027926 WO2012122193A1 (en) | 2011-03-07 | 2012-03-06 | Methods and compositions for treating depression using cyclobenzaprine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DK2683245T3 true DK2683245T3 (da) | 2020-02-24 |
| DK2683245T4 DK2683245T4 (da) | 2023-01-09 |
Family
ID=46796107
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK12755254.5T DK2683245T4 (da) | 2011-03-07 | 2012-03-06 | Fremgangsmåder og sammensætninger til behandling af depression ved anvendelse af cyclobenzaprin |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20120232159A1 (da) |
| EP (2) | EP2683245B2 (da) |
| JP (2) | JP2014507475A (da) |
| AU (4) | AU2012225548B2 (da) |
| CA (1) | CA2829200C (da) |
| CY (1) | CY1122998T1 (da) |
| DK (1) | DK2683245T4 (da) |
| ES (1) | ES2773834T5 (da) |
| FI (1) | FI2683245T4 (da) |
| HR (1) | HRP20200142T4 (da) |
| HU (1) | HUE048596T2 (da) |
| LT (1) | LT2683245T (da) |
| PL (1) | PL2683245T5 (da) |
| PT (1) | PT2683245T (da) |
| RS (1) | RS60240B2 (da) |
| SI (1) | SI2683245T2 (da) |
| WO (1) | WO2012122193A1 (da) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2501234B1 (en) * | 2009-11-20 | 2017-09-13 | Tonix Pharma Holdings Limited | Methods and compositions for treating symptoms associated with post-traumatic stress disorder using cyclobenzaprine |
| US20110319389A1 (en) | 2010-06-24 | 2011-12-29 | Tonix Pharmaceuticals, Inc. | Methods and compositions for treating fatigue associated with disordered sleep using very low dose cyclobenzaprine |
| US10117936B2 (en) | 2013-03-15 | 2018-11-06 | Tonix Pharma Holdings Limited | Eutectic formulations of cyclobenzaprine hydrochloride and amitriptyline hydrochloride |
| WO2015150948A1 (en) * | 2014-03-29 | 2015-10-08 | Wockhardt Limited | Modified release solid oral pharmaceutical compositions of cyclobenzaprine or a salt thereof |
| CA2961822A1 (en) | 2014-09-18 | 2016-03-24 | Tonix Pharma Holdings Limited | Eutectic formulations of cyclobenzaprine hydrochloride |
| CN106890129A (zh) * | 2015-12-18 | 2017-06-27 | 健乔信元医药生技股份有限公司 | 环苄普林之延释剂型 |
| CA3083341A1 (en) | 2017-12-11 | 2019-06-20 | Tonix Pharma Holdings Limited | Cyclobenzaprine treatment for agitation, psychosis and cognitive decline in dementia and neurodegenerative conditions |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| US5354566A (en) | 1993-06-02 | 1994-10-11 | Kraft General Foods, Inc. | Preparation of yeast-leavened dough crusts |
| IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| US6267985B1 (en) | 1999-06-30 | 2001-07-31 | Lipocine Inc. | Clear oil-containing pharmaceutical compositions |
| US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| US6761903B2 (en) | 1999-06-30 | 2004-07-13 | Lipocine, Inc. | Clear oil-containing pharmaceutical compositions containing a therapeutic agent |
| US6383471B1 (en) | 1999-04-06 | 2002-05-07 | Lipocine, Inc. | Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents |
| US6309663B1 (en) | 1999-08-17 | 2001-10-30 | Lipocine Inc. | Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents |
| ES2192156B1 (es) * | 1999-08-13 | 2005-02-16 | Vela Pharmaceuticals, Inc. | Composiciones de uso para tratar o prevenir alteraciones del sueño usando dosis muy bajas de ciclobenzaprina. |
| MXPA02001568A (es) * | 1999-08-13 | 2002-07-02 | Vela Pharmaceuticals Inc | Ciclobenzaprina para tratar trastornos de ansiedad generalizada y composiciones de la misma. |
| US6720001B2 (en) | 1999-10-18 | 2004-04-13 | Lipocine, Inc. | Emulsion compositions for polyfunctional active ingredients |
| CA2543710A1 (en) * | 2003-11-03 | 2005-05-12 | Warner-Lambert Company Llc | Novel norepinephrine reuptake inhibitors for the treatment of central nervous system disorders |
| US20050143350A1 (en) * | 2003-11-19 | 2005-06-30 | Seed John C. | Combination drug therapy to treat obesity |
| US7532935B2 (en) * | 2005-07-29 | 2009-05-12 | Cyberonics, Inc. | Selective neurostimulation for treating mood disorders |
| US7994220B2 (en) * | 2005-09-28 | 2011-08-09 | Cypress Bioscience, Inc. | Milnacipran for the long-term treatment of fibromyalgia syndrome |
| JP5714910B2 (ja) * | 2008-01-09 | 2015-05-07 | チャールストン ラボラトリーズ，インコーポレイテッド | 薬学的組成物 |
-
2012
- 2012-03-05 US US13/412,571 patent/US20120232159A1/en active Pending
- 2012-03-06 AU AU2012225548A patent/AU2012225548B2/en active Active
- 2012-03-06 FI FIEP12755254.5T patent/FI2683245T4/fi active
- 2012-03-06 HR HRP20200142TT patent/HRP20200142T4/hr unknown
- 2012-03-06 EP EP12755254.5A patent/EP2683245B2/en active Active
- 2012-03-06 LT LTEP12755254.5T patent/LT2683245T/lt unknown
- 2012-03-06 CA CA2829200A patent/CA2829200C/en active Active
- 2012-03-06 WO PCT/US2012/027926 patent/WO2012122193A1/en active Application Filing
- 2012-03-06 RS RS20200155A patent/RS60240B2/sr unknown
- 2012-03-06 ES ES12755254T patent/ES2773834T5/es active Active
- 2012-03-06 DK DK12755254.5T patent/DK2683245T4/da active
- 2012-03-06 PL PL12755254.5T patent/PL2683245T5/pl unknown
- 2012-03-06 JP JP2013557811A patent/JP2014507475A/ja active Pending
- 2012-03-06 EP EP19214568.8A patent/EP3682885A1/en not_active Withdrawn
- 2012-03-06 SI SI201231736T patent/SI2683245T2/sl unknown
- 2012-03-06 PT PT127552545T patent/PT2683245T/pt unknown
- 2012-03-06 HU HUE12755254A patent/HUE048596T2/hu unknown
-
2016
- 2016-01-18 JP JP2016007041A patent/JP2016053095A/ja active Pending
- 2016-08-31 AU AU2016222412A patent/AU2016222412B2/en active Active
-
2018
- 2018-06-26 AU AU2018204633A patent/AU2018204633C1/en active Active
-
2020
- 2020-02-05 CY CY20201100112T patent/CY1122998T1/el unknown
- 2020-06-11 AU AU2020203874A patent/AU2020203874B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2890780T3 (da) | Fremgangsmåder og sammensætninger til behandling af en genetisk tilstand | |
| DK4011364T3 (da) | Fremgangsmåder og sammensætninger til behandling af ADD (Attention Deficit Disorder) | |
| DK2709613T4 (da) | Fremgangsmåder til behandling af hcv | |
| DK2900061T3 (da) | Fremgangsmåde til forstærkning af specifikke immunterapier ved cancerbehandling | |
| DK2914741T3 (da) | Hidtil ukendte sammensætninger og fremgangsmåder til forbedring af PCR-specificitet | |
| DK2776567T3 (da) | Sammensætninger og fremgangsmåder til behandling af cytomegalovirus. | |
| DK2812452T3 (da) | Fremgangsmåder og sammensætninger til screening og behandling af udviklingsforstyrrelser | |
| DK3141542T3 (da) | Substituerede benzaldehydforbindelser og fremgangsmåder til anvendelse deraf ved øgning af vævsiltning | |
| DK2768321T3 (da) | Fremgangsmåder og sammensætninger til induktion af mæthed | |
| BR112013019732A2 (pt) | composições e métodos para tratamento de doenças cardiovasculares | |
| DK3586861T3 (da) | Lipidnanopartikelsammensætninger og fremgangsmåder til mrna-indgivelse | |
| DK2699553T3 (da) | Substituerede diaminocarboxamid- og diaminocarbonitrilpyrimidiner, sammensætninger deraf og fremgangsmåder til behandling dermed | |
| DK2884999T3 (da) | Fremgangsmåde og sammensætninger til cellulær immunterapi | |
| DK2739293T3 (da) | Fremgangsmåder og sammensætninger til frembringelse af vaccinavirus | |
| DK2583586T4 (da) | Indretning til registrering af kollisioner og tilsvarende fremgangsmåde | |
| DK2766483T3 (da) | Fremgangsmåder og sammensætninger til screening for og behandling af udviklingsforstyrrelser | |
| DK2552484T3 (da) | Fremgangsmåder og sammensætninger til reducering af parathyroidniveauer | |
| DK2793895T3 (da) | Fremgangsmåder og sammensætninger til reducering af kropsfedt og adipocytter | |
| DK2683245T4 (da) | Fremgangsmåder og sammensætninger til behandling af depression ved anvendelse af cyclobenzaprin | |
| DK2830654T3 (da) | Metoder og sammensætninger til behandling af inflammation | |
| DK2680829T3 (da) | Sammensætninger og metoder til ikke-kirurgisk behandling af ptosis | |
| DK2877856T3 (da) | Fremgangsmåde til forbedring af implantationssucces ved assisteret befrugtning | |
| DK2917231T3 (da) | Lipopeptider til anvendelse ved behandling af leversygdomme og hjerte-kar-sygdomme | |
| DK2442832T3 (da) | Sammensætninger og fremgangsmåder til behandling af dissemineret sclerose | |
| DK2683371T3 (da) | Forbindelser og fremgangsmåder til forbedring af forringet endogen fibrinolyse ved anvendelse af histondeacetylasehæmmere |